Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19.6M
-
Number of holders
-
217
-
Total 13F shares, excl. options
-
15.4M
-
Shares change
-
-7.02M
-
Total reported value, excl. options
-
$2.35B
-
Value change
-
-$956M
-
Put/Call ratio
-
2.02
-
Number of buys
-
82
-
Number of sells
-
-143
-
Price
-
$152.45
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q1 2021
280 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q1 2021.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 217 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.4M shares
of 19.6M outstanding shares and own 78.7% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.13M shares), VANGUARD GROUP INC (1.52M shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (1.29M shares), JANUS HENDERSON GROUP PLC (1.26M shares), STATE STREET CORP (783K shares), VILLERE ST DENIS J & CO LLC (537K shares), Conestoga Capital Advisors, LLC (496K shares), MACQUARIE GROUP LTD (484K shares), Chicago Capital, LLC (449K shares), and RICE HALL JAMES & ASSOCIATES, LLC (430K shares).
This table shows the top 217 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.